Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Tumor vasculature is a key target for anticancer drug development.
• Antiangiogenic cancer therapy inhibits tumor angiogenesis.
• Preclinical models show potent antiangiogenic effects, but clinical benefits are modest.

Purpose of the Study:

• To address the disparity between preclinical antiangiogenic drug (AD) efficacy and clinical outcomes.
• To critically evaluate the suitability of current animal tumor models for AD clinical development.
• To explore key differences between mouse models and human cancer patients regarding AD response.

Main Methods:

• Review of existing literature on antiangiogenic therapy.
• Analysis of preclinical data versus clinical trial results for ADs.
• Discussion of potential off-target effects and alternative strategies.

Main Results:

• Significant disconnect exists between antiangiogenic monotherapy efficacy in preclinical models and clinical benefit.
• Combination therapy with chemotherapy shows only modest survival improvements in some cancers.
• Current animal models may not accurately predict human patient responses to ADs.

Conclusions:

• Re-evaluation of preclinical models is crucial for assessing therapeutic efficacy of ADs.
• Understanding differences between mouse models and human patients is essential for effective AD development.
• Exploring alternative strategies is necessary to enhance clinical benefits of antiangiogenic drugs.